
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of 1 Preventive Medicine and 2 Obstetrics and Gynecology, Keck School of Medicine, University of Southern California, Los Angeles and 3 Epidemiology Program, Cancer Research Center of Hawaii, University of Hawaii, Honolulu, Hawaii
Requests for reprints: Veronica Wendy Setiawan, University of Southern California/Norris Comprehensive Cancer Center, 1441 Eastlake Avenue, Room 4425, Los Angeles, CA 90033. Phone: 323-865-0411; Fax: 323-865-0127. E-mail: vsetiawa{at}usc.edu
| Abstract |
|---|
|
|
|---|
0.004). Across racial/ethnic groups, Native Hawaiians had the highest mean levels of androstenedione, testosterone, and estrogens and the lowest mean levels of SHBG. Compared with Whites, Native Hawaiians had higher androstenedione (+22%, P = 0.017), total testosterone (+26%, P = 0.013), bioavailable testosterone (+33%, P = 0.002), E1 (
21%; P = 0.009), total E2 (+26%, P = 0.001), bioavailable E2 (+31%, P < 0.001), and lower SHBG (12% P = 0.07) levels. Compared with Whites, Japanese Americans had higher E2 (+15%, P = 0.036) and bioavailable E2 (+18%, P = 0.024) levels. African Americans also had higher E1 (+21%, P = 0.004), E2 (+20%, P = 0.007), and bioavailable E2 (+20%, P = 0.015) levels compared with Whites, whereas mean levels in Latinas were similar to those of Whites. Many of the differences in endogenous postmenopausal hormonal milieu across these five racial/ethnic groups are consistent with the known differences in breast cancer incidence across these populations. (Cancer Epidemiol Biomarkers Prev 2006;15(10):184955) | Introduction |
|---|
|
|
|---|
A large and compelling body of epidemiologic and experimental data implicates endogenous estrogens in the etiology of breast cancer (8). Results of a pooled analysis of nine prospective studies provide evidence for an important role of estrogens and their androgen precursors in the development of breast cancer in postmenopausal women (9). The relative risks of breast cancer for women whose estrogen and androgen levels were in the top quintile compared with those whose levels were in the bottom quintile were
2. The results also showed that women with high circulating sex hormonebinding globulin (SHBG) levels, a protein that binds to and restricts the biological activity of estradiol and testosterone, had lower breast cancer risk (9).
Racial/ethnic differences in endogenous sex hormone levels might explain some of the variation in breast cancer incidence across racial/ethnic groups. There are only a small number of studies on differences in endogenous hormone levels between racial/ethnic groups in the United States (10-15), and comparisons with Native Hawaiians have not been reported. In the present study, we examined racial/ethnic differences in postmenopausal sex steroid hormone concentrations in a cross-sectional study of 739 postmenopausal women from the MEC (240 African Americans, 81 Native Hawaiians, 96 Japanese Americans, 231 Latinas, and 91 Whites).
| Materials and Methods |
|---|
|
|
|---|
Incident breast cancer cases were identified by record linkage to the Hawaii Tumor Registry, the Cancer Surveillance Program for Los Angeles County, and the California State Cancer Registry. All tumor registries participate in the National Cancer Institute's Surveillance, Epidemiology and End Results program of cancer registration. Deaths within the cohort were determined by annual linkage to state death certificate files in California and Hawaii and periodically to the National Death Index. Case ascertainment and death information were complete through December 31, 2002.
Beginning in 1994, blood samples were collected from a random sample of MEC participants to serve as a control pool for genetic association studies. Blood samples were collected at the participants' homes after an overnight fast, processed within 8 hours, and stored at 80°C.
Study Population
Subjects of this study were drawn from the control group of the MEC nested case-control study of breast cancer. Details of this case-control study have been previously published (17). Women were selected for hormone measurements if they met all of the following criteria:
56 years old at the time of blood draw, reported no history of breast, endometrial or ovarian cancer on the baseline questionnaire, body weight and body mass index (BMI) information available, and not using postmenopausal hormones at baseline and at the time of blood draw. Seven hundred thirty-nine women were included in this study; of these, 240 were African Americans, 81 were Native Hawaiians, 96 were Japanese Americans, 231 were Latinas, and 91 were Whites. The mean age at blood draw was 66.9 years, ranging from 56 to 82 years. All study participants have provided informed consent, and the Institutional Review Boards at the University of Hawaii and at the University of Southern California approved the protocol.
Hormone Assays
Plasma hormone assays were done at the Reproductive Endocrine Research Laboratory at the University of Southern California, directed by one of the authors (F.Z.S.). All samples across ethnic groups were assayed together and samples from each ethnic group were included within each batch. Samples were also blinded so that laboratory personnel could not identify which ethnic group the samples were from. Plasma concentrations of androstenedione, testosterone, estrone (E1), and estradiol (E2) were measured by sensitive and specific immunoassays after organic solvent extraction and Celite column partition chromatography. SHBG were quantified by a solid-phase, two-site chemiluminescent immunoassay, using the Immulite analyzer (Diagnostic Products Corp., Inglewood, CA). Bioavailable (non-SHBG bound) testosterone and E2 concentrations were calculated using a validated algorithm on the basis of total testosterone, total E2, and SHBG measurements (18-20). Replicate-blinded quality control samples (5%) were included to check reproducibility of the hormone assays; the intraclass correlation coefficients between duplicates for androstenedione, testosterone, E1, E2, and SHBG were 0.89, 0.98, 0.87, 0.82, and 0.98, respectively. In addition, quality control samples with low, medium, and high concentrations (one pair per level) were included in each batch. The interassay coefficients of variation for sex steroid hormones were
14%,
12%, and
13% at low, medium, and high levels, respectively. The interassay coefficients of variation for SHBG were all
5%.
Statistical Methods
Twenty-two postmenopausal women with either E1 values >125 pg/mL, E2 values >75 pg/mL, or testosterone values >125 ng/dL (indicating postmenopausal hormone use) were excluded from the study. Three women (<60 years old at blood draw) who either had unknown menopausal status or were premenopausal at baseline had E2 values >75 pg/mL and were also excluded from the study, leaving 714 women available for the analyses. Information on breast cancer risk factors and other lifestyle factors that might influence hormone levels (21-36) was obtained from the MEC baseline questionnaire. These factors were body weight, height, age at menarche, age at first birth, parity, age and type of menopause, alcohol drinking, smoking status, vigorous physical activity, calorie intake, percent calories from fat, dietary fiber intake, and soy intake. BMI was calculated as weight (kg)/height (m)2. The median interval between baseline questionnaire date and blood draw was 4 years (range, 1-8 years). All hormone values were natural log-transformed to produce approximately normal distributions. Geometric mean hormone levels according to race/ethnicity were calculated using multivariate regression analysis while adjusting for age at blood draw and assay batch. Further adjustment was also done for risk/lifestyle factors that were significantly associated with a particular hormone fraction. These risk factors included BMI and soy intake that were modeled as continuous variables, and age at menarche (
12, 13-14, and
15 years), age and type of menopause [natural (<44, 45-49,
50 years), bilateral oophorectomy (<44,
45 years), hysterectomy (<44,
45 years), and unknown], and smoking status (never, past, and current), which were modeled as categorical variables. Analysis of covariance was used to test for differences in mean hormone levels across race/ethnicity, and Ps for heterogeneity of effects across groups were also reported. For racial/ethnic differences, the main comparison group was White women, as this group had been used as the comparison group in a previous study (11). Breast cancer incidence rates in the MEC were calculated among women ages
55 years at baseline and included all incident cases of breast cancer through December 31, 2002. Rates were truncated to age 55 to 79 years and age-adjusted to the U.S. 1970 standard population. All Ps are two sided. The SAS statistical package version 9.0 (SAS Institute, Cary, NC) was used for all analyses.
| Results |
|---|
|
|
|---|
|
0.05). Age and type of menopause was associated with difference in testosterone levels (Ps <0.001). We observed that smoking was associated with differences in androgen levels but not with estrogen or SHBG levels. Increasing soy intake was modestly related with lower testosterone levels (P = 0.04). No statistically significant relationships were observed between hormone levels and vigorous physical activity, alcohol drinking, calorie intake, and proportion calories from fat or fiber intake. Ethnic-specific associations between selected risk/lifestyle factors and hormone levels are provided in Supplementary Table S1.
|
|
African Americans in our study had higher age-adjusted mean levels of E1 (+24% P = 0.002), E2 (+25% P = 0.002), and bioavailable E2 (+26% P = 0.005) compared with Whites; further adjustment for risk factors (BMI and age at menarche) reduced these differences, but they remained statistically significant. In the multivariate models, African-American women had 21% higher E1 (P = 0.004), 20% higher E2 (P = 0.007), and 20% higher bioavailable E2 (P = 0.015) levels compared with White women. Across ethnic groups, African Americans had the highest levels of SHBG despite being the heaviest group. Compared with Native Hawaiians, they had 22% higher SHBG levels (P = 0.001), but compared with Whites, the difference in SHBG levels was not significant (+7%, P = 0.224).
In age-adjusted analyses, Japanese-American women had similar mean hormone levels to that of Whites. However, after adjustment for BMI and age at menarche, Japanese Americans were found to have 15% higher E2 (P = 0.036) and 18% higher bioavailable E2 (P = 0.024) levels than Whites.
There were no significant differences in plasma hormone concentrations between Latina and White women.
In our cohort, the prevalence of bilateral oophorectomy varied across ethnic groups, and this might influence ethnic differences in testosterone levels; we, thus, repeated our analyses while excluding women who had reported bilateral oophorectomy on the questionnaire (n = 72). We observed similar results before and after the exclusion of women with a bilateral oophorectomy. We also repeated our analyses while restricting the analyses to women with covariate data collected within 4 or 5 years of blood draw, and our results did not change.
In our study, 13% of the Japanese-American and 46% of Latina women were born outside the United Stated. Compared with U.S. born Japanese, Japanese women born outside the United States had lower levels of androgens and estrogens and higher levels of SHBG; but these differences were not statistically significant (data not shown). U.S. born and foreign-born Latina women had similar hormone profiles. Adjusting for birthplace in the multivariate models did not alter our results (data not shown).
| Discussion |
|---|
|
|
|---|
Compared with Whites, Native Hawaiians were found to have higher circulating levels of androgens and estrogens; differences that were not accounted for by the racial/ethnic differences in the prevalence of breast cancer risk factors and other lifestyle factors. We have previously shown that after adjustment for seven known breast risk factors (age at menarche and first birth, parity, age and type of menopause, weight, postmenopausal hormone use, and alcohol intake), the breast cancer risk for Native Hawaiians was 65% greater than that of Whites (7). The Native Hawaiians' "high-risk" hormonal profile is consistent with their high rates of breast cancer and suggests that the excess breast cancer risk in Native Hawaiians may be due to their having high plasma androgen and estrogen levels and low SHBG levels.
The low postmenopausal estrogen levels of Japanese women living in Japan (12) were not observed in the Japanese-American women in this study, most of whom (87%) were U.S. born. In our study, Japanese Americans had adjusted mean levels of E2 that were significantly higher than those of Whites. In a previous smaller study conducted among 193 postmenopausal women in the MEC, Japanese-American women (n = 30), despite their low body weight, had 32% higher E1 and E2 levels as high as White women (n = 39; ref. 11). Although the magnitude of mean differences in hormone levels between these two ethnic groups was much smaller in the current study, our findings provide support for the previous observation in the initial report. In the MEC, the risk factor adjusted incidence of breast cancer among Japanese Americans was slightly higher than Whites (7). The elevated E2 levels in Japanese Americans may provide an explanation for their increase in incidence of breast cancer, and that increases in estrogen levels and breast cancer rates may both be determined by long-term exposure to a western diet and other lifestyle factors.
It is well documented that African-American women have higher premenopausal breast cancer rates and lower postmenopausal rates relative to White women (38). Most (10, 13, 15, 39) but not all (40, 41) studies in premenopausal women have reported that African Americans had higher E2 levels than Whites. In the MEC, the incidence of postmenopausal breast cancer in African Americans was also lower than in Whites; however, their endogenous estrogen levels were found to be significantly higher than those of Whites, confirming findings from an earlier and smaller study in the MEC (11). If having elevated estrogen levels contribute to their higher rates during the premenopausal period, then it is interesting to find out why this elevation does not persist into the postmenopausal period when their estrogen levels are also elevated. Clearly, more work is needed to identify the factors that contribute to these racial/ethnic differences in risk that exist in the premenopausal and postmenopausal periods.
Latinas had sex steroid hormone profiles that were very similar to Whites, in accord with our previous results from a smaller study of 58 Latina postmenopausal women (11). In the MEC, postmenopausal breast cancer risk among U.S. born Latinas was found to be similar to Whites (relative risk, 0.95; 95% confidence interval, 0.75-1.20), whereas migrant Latinas had 16% lower risk than Whites (relative risk, 0.84; 95% confidence interval, 0.64-1.10; ref. 7). We observed that U.S. born and migrant Latinas had similar hormone profiles.
The factors underlying racial/ethnic variation in postmenopausal sex steroid hormone levels are largely unknown; other than body weight or BMI, little is known about their determinants. Variation in key genes involved in estrogen biosynthesis pathway have been associated with differences in circulating hormone levels (42-49); thus, some of the observed ethnic differences in hormone levels may be ascribed to the differences in the distributions of polymorphisms in these genes. Additional research, however, will be needed to test this hypothesis.
Low response rates in certain ethnic groups may affect generalizability of our results to the general population. The response rates in our cohort ranged from 20% in Latinos to 49% in Japanese Americans. As previously shown, however, the distributions of education level in our cohort generally resemble those reported by the U.S. Census in Hawaii and Los Angeles County for the same ethnic and age groups; thus, we believe that findings from this cohort can be compared across ethnic and social strata and are broadly generalizable (16).
In summary, this study confirms the existence of racial/ethnic differences in endogenous sex hormone levels and adds to the sparse data available in the Latino and Native Hawaiian population. Future research should be aimed to elucidate the determinants of Native Hawaiians' high-risk hormonal profiles and increasing E2 levels in Japanese Americans and to clarify the relationship between sex steroid hormones and breast cancer risk in postmenopausal African-American women.
| Acknowledgments |
|---|
| Footnotes |
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Note: Supplementary data for this article are available at Cancer Epidemiology, Biomarkers and Prevention Online (http://cebp.aacrjournals.org/).
Received 4/17/06; revised 6/12/06; accepted 7/25/06.
| References |
|---|
|
|
|---|
gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res 1998;58:5857.This article has been cited by other articles:
![]() |
A. H Wu, M. C Yu, C.-C. Tseng, F. Z Stanczyk, and M. C Pike Dietary patterns and breast cancer risk in Asian American women Am. J. Clinical Nutrition, April 1, 2009; 89(4): 1145 - 1154. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. H. Wu, G. Ursin, W.-P. Koh, R. Wang, J.-M. Yuan, K.-S. Khoo, and M. C. Yu Green Tea, Soy, and Mammographic Density in Singapore Chinese Women Cancer Epidemiol. Biomarkers Prev., December 1, 2008; 17(12): 3358 - 3365. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Linos, D. Spanos, B. A. Rosner, K. Linos, T. Hesketh, J. D. Qu, Y.-T. Gao, W. Zheng, and G. A. Colditz Effects of Reproductive and Demographic Changes on Breast Cancer Incidence in China: A Modeling Analysis J Natl Cancer Inst, October 1, 2008; 100(19): 1352 - 1360. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. W. Setiawan, F. R. Schumacher, C. A. Haiman, D. O. Stram, D. Albanes, D. Altshuler, G. Berglund, J. Buring, E. E. Calle, F. Clavel-Chapelon, et al. CYP17 Genetic Variation and Risk of Breast and Prostate Cancer from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3) Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2237 - 2246. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Z. Stanczyk, J. S. Lee, and R. J. Santen Standardization of Steroid Hormone Assays: Why, How, and When? Cancer Epidemiol. Biomarkers Prev., September 1, 2007; 16(9): 1713 - 1719. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Palmer, L. L. Adams-Campbell, D. A. Boggs, L. A. Wise, and L. Rosenberg A Prospective Study of Body Size and Breast Cancer in Black Women Cancer Epidemiol. Biomarkers Prev., September 1, 2007; 16(9): 1795 - 1802. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Haiman, L. Dossus, V. W. Setiawan, D. O. Stram, A. M. Dunning, G. Thomas, M. J. Thun, D. Albanes, D. Altshuler, E. Ardanaz, et al. Genetic Variation at the CYP19A1 Locus Predicts Circulating Estrogen Levels but not Breast Cancer Risk in Postmenopausal Women Cancer Res., March 1, 2007; 67(5): 1893 - 1897. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |